Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products > Novel inhibitors

Novel inhibitors

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DCC4913 St029248
Novel potent mast cell (MC) activator, promoting de novo synthesis of cytokines and inducing the release of eicosanoids from human and mouse MCs
More description
DCC4912 St026567
Novel potent mast cell (MC) activator, promoting de novo synthesis of cytokines and inducing the release of eicosanoids from human and mouse MCs
More description
DCC4911 Sstr5a
Novel somatostatin receptor subtype 5 antagonist, stimulating glucoseinduced GLP-1 secretion, reducing blood glucose in a gut- and GLP-1R-dependent manner
More description
DCC4910 Sstr3-antagonist-3a
Novel potent sstr3 antagonist, showing to reduce glucose excursion in a mouse oGTT assay
More description
DCC4909 Sstr3-agonist-5c
Novel non-peptidic highly potent somatostatin receptor 3 (SSTR3) agonist
More description
DCC4908 SS-thujaplicinol
Inhibitor of the replication of herpes simplex viruses 1 and 2 (HSV-1 and HSV-2)
More description
DCC4906 Ssr126768a
Novel Selective and Orally Active Oxytocin Receptor Antagonist for the Prevention of Preterm Labor
More description
DCC4905 SS-nicotinamide Adenine Dinucleotide, Reduced Disodium
Cofactor for mitochondrial deacetylase sirtuin-3 enzyme, regulating energy metabolism and immunity and modulating inflammasome assembly
More description
DCC4904 SS-nf-jq1
Novel chimeric degrader against bromodomain-containing (BRD) proteins, inducing the interaction of AhR and BRD proteins and displaying effective anticancer activity that correlated with protein knockdown activity
More description
DCC4903 SS-nf-atra
Novel chimeric degrader against cellular retinoic acid binding proteins (CRABPs), inducing the AhR-dependent degradation of CRABP-1 and CRABP-2 via the ubiquitin-proteasome pathway
More description
DCC4902 Ssm3 Tfa Salt
Potent furin inhibitor, blocking furin-dependent cell surface processing of anthrax protective antigen-83 in vitro.
More description
DCC4901 SS-lysine
Elongation factor P (EF-P) fuction modifier
More description
DCC4900 Ssj-183
Novel antimalarial agent
More description
DCC4899 SS-hydroxymethyl Chalcone
The first selective inhibitor of Histone Deacetylase 2 (HDAC2)
More description
DCC4898 SS-elemene
Novel inhibitor of Pak1 activation, anti-cancer ingredient isolated from the Chinese traditional herb Curcuma wenyujin
More description
DCC4897 SS-cit Tartrate
Non-selective potent dopamine reuptake inhibitor
More description
DCC4896 SS-cit
Non-selective potent dopamine reuptake inhibitor
More description
DCC4895 SS-carboline-1-carboxylic Acid
Potent competitive inhibitor of indoleamine 2,3-dioxygenase (IDO)
More description
DCC4894 SS-amyloid-in-7l
Potent ß-amyloid aggregation inhibitor; Antioxidant
More description
DCC4893 Ss1020
Novel antiestrogen, lacking estrogenic and genotoxic actions
More description
DCC4892 Srta-in-i
Novel potent inhibitor of Staphylococcus aureus sortase A (SrtA)
More description
DCC4891 Srt3190 (2s,3r)
Novel selective CXCR2 antagonist
More description
DCC4890 Srt3025 Hydrochloride
Novel potent SIRT1 activator
More description
DCC4889 Srt3025
Novel Sirtuin1 Activator, Down-Regulating Sclerostin and Rescuing Ovariectomy-Induced Bone Loss
More description
DCC4888 Sri-39067
Novel MOR agonist/DOR antagonist that produced systemically active potent antinociceptive activity in tail-flick assay in mice
More description
DCC4887 Sri-37684
Novel GLUT inhibitor, preferentially inhibiting the growth of GBM cells with minimal toxicity to non-neoplastic astrocytes and neurons, also inhibiting glucose uptake and decrease the glycolytic capacity and glycolytic reserve capacity of GBM patient-deri
More description
DCC4886 Sri-37683
Novel GLUT inhibitor, preferentially inhibiting the growth of GBM cells with minimal toxicity to non-neoplastic astrocytes and neurons, also inhibiting glucose uptake and decrease the glycolytic capacity and glycolytic reserve capacity of GBM patient-deri
More description
DCC4885 Sri-36160
Novel potent inhibitor of Wn/ß-catenin signaling in cancer cells
More description
DCC4884 Sri-35241
Novel inhibitor of thrombospondin 1 activation of TGF-β, blocking TGF-β activation (pIC50 = 8.12 nM) and has a plasma half life of 1.8 h (iv)
More description
DCC4883 Sri-31040
Potent DAT allosteric modulator, partially inhibiting DAT uptake without altering DAT-mediated reverse transport and with minimal inhibition of DAT binding
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X